Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ADCE-B05

Phase 1Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid Tumors (phase 1)Recruiting

Solid Tumors (phase 1)Phase 1

Recruiting

Timeline

Expected Milestones

Q1 2029

Phase 1Recruiting

Study completion

NCT07362888

Clinical

Trials by Indication[1]

Unspecified1 trial

A First-in-Human, Phase 1a/1b, Open-Label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of the Antibody Drug Conjugate ADCE-B05 in Patients With Advanced Solid Tumors

Recruiting·AAdcendo ApS·Phase 1·NCT07362888·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ADCE-B05. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ADCE-B05 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ADCE-B05. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Adcendo ApS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAdcendo ApS

Related News